United Kingdom Ulcerative Colitis Market is Anticipated to Witness High Growth Owing to Increasing Disease Incidence Rates

United Kingdom Ulcerative Colitis Market is Anticipated to Witness High Growth Owing to Increasing Disease Incidence Rates

Ulcerative colitis refers to a type of inflammatory bowel disease (IBD) which causes long-lasting inflammation and sores, known as ulcers, in the lining of the large intestine. The disease commonly affects the rectum and lower part of the colon resulting in symptoms of abdominal cramps, rectal bleeding and frequent bloody diarrhea. The increasing incidence rates of ulcerative colitis in the UK have boosted demand for various treatment options including pharmaceutical drugs and biologics.

The United Kingdom Ulcerative Colitis Market Size is estimated to be valued at US$ 421.3 Mn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the United Kingdom ulcerative colitis market are AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson and Among Others.

AbbVie Inc., through its key brands such as Humira and Lupron, dominates the overall UK IBD treatment market. The company holds a significant market share owing to its wide product portfolio and strong brand recognition.

The rising research and development activities in developing novel biologics for ulcerative colitis treatment is expected to open new avenues of growth for market players in the UK. In addition, growing adoption of biosimilars will further fuel the market expansion over the coming years.

Increase in partnerships between drug makers and expansion of clinical pipelines are some key trends witnessed among major players in the UK market. Growing health awareness among patients has also contributed to the overall market growth.

Market Drivers and Restrain

The increasing incidence and prevalence of ulcerative colitis across the UK acts as a key market driver. According to a report by the National Institute for Health and Care Excellence (NICE), it is estimated that over 146,000 people were living with ulcerative colitis in the UK in 2016. The rising disease burden has boosted the demand for various treatment options including pharmaceutical drugs and biologics.

Growing research and development activities focused on developing novel treatment regimens is another major factor fueling the market growth. Several pharmaceutical companies are collaborating with research institutes to explore new drugs and therapeutics for ulcerative colitis.

However, high costs associated with biologics and biosimilars hampers their widespread adoption and acts as a market restrain. Moreover, lack of disease awareness in some regions of the UK also impedes the market growth to some extent.

Segment Analysis 

The United Kingdom ulcerative colitis market is segmented based on drug class, route of administration, distribution channel and end user. Based on drug class, the market is dominated by aminosalicylates sub segment which accounts for more than 30% share due to its effectiveness and affordability. Among aminosalicylates, Mesalamine dominates as it is the first line therapy for UC patients with mild to moderate symptoms. Based on route of administration, the oral segment holds the largest share due to ease of administration compared to other segments.

Global Analysis

Regionally, Western Europe accounts for the largest share in the United Kingdom ulcerative colitis market on account of developed healthcare infrastructure and awareness levels. North America follows Western Europe due to rising prevalence of Inflammatory Bowel Disease. Asia Pacific region will witness fastest growth rate during the forecast period owing to improvements in diagnostic facilities and adoption of advanced treatment options. Key players are focusing on geographical expansion plans in emerging markets to leverage growth opportunities.

What Are The Key Data Covered In This United Kingdom Ulcerative Colitis Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the United Kingdom Ulcerative Colitis's growth between 2024 and 2031.

:- Accurate calculation of the size of the United Kingdom Ulcerative Colitis and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- United Kingdom Ulcerative Colitis Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of United Kingdom Ulcerative Colitis vendors

FAQ’s

Q.1 What are the main factors influencing the United Kingdom Ulcerative Colitis?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top United Kingdom Ulcerative Colitis companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the United Kingdom Ulcerative Colitis’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.marketwebjournal.com/united-kingdom-ulcerative-colitis-market-trend-size-and-demand-2/